

Joel W Hay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4534610/publications.pdf>

Version: 2024-02-01

136
papers

5,004
citations

117625

34
h-index

98798

67
g-index

141
all docs

141
docs citations

141
times ranked

6095
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Fexapotide trifluate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis. <i>BMC Urology</i> , 2022, 22, 76. | 1.4 | 0 |
| 2 | Reconstruction After Salvage Total Laryngectomy: A Cost-Effectiveness Analysis. <i>Otolaryngology - Head and Neck Surgery</i> , 2021, 164, 139-145. | 1.9 | 5 |
| 3 | The Assessment of Different Diets and Mortality Fails to Address Unmeasured Confounding. <i>JAMA Internal Medicine</i> , 2021, 181, 137. | 5.1 | 0 |
| 4 | A US Population Health Survey on the Impact of COVID-19 Using the EQ-5D-5L. <i>Journal of General Internal Medicine</i> , 2021, 36, 1292-1301. | 2.6 | 51 |
| 5 | Cost-effectiveness of bezlotoxumab and fidaxomicin for initial <i>Clostridioides difficile</i> infection. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1448-1454. | 6.0 | 14 |
| 6 | Diagnosing newborns with suspected mitochondrial disorders: an economic evaluation comparing early exome sequencing to current typical care. <i>Genetics in Medicine</i> , 2021, 23, 1854-1863. | 2.4 | 4 |
| 7 | Where Do We Go From Here? A Framework for Using Susceptible-Infectious-Recovered Models for Policy Making in Emerging Infectious Diseases. <i>Value in Health</i> , 2021, 24, 917-924. | 0.3 | 5 |
| 8 | Neonates with mild hypoxic-ischaemic encephalopathy receiving supportive care versus therapeutic hypothermia in California. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2021, , fetalneonatal-2021-322250. | 2.8 | 7 |
| 9 | Quality of Life in the Swedish General Population During COVID-19 - Based on pre- and post-pandemic outbreak measurement. <i>Nordic Journal of Health Economics</i> , 2021, 9, 56-73. | 0.2 | 7 |
| 10 | There is Insufficient Evidence to Support a Causal Relationship Between Chili Pepper Consumption and Mortality. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1864. | 2.8 | 5 |
| 11 | Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 428-434. | 1.3 | 6 |
| 12 | Cost-Effectiveness Analysis of Four Common Diagnostic Methods for <i>Clostridioides difficile</i> Infection. <i>Journal of General Internal Medicine</i> , 2020, 35, 1102-1110. | 2.6 | 6 |
| 13 | Hypertension and Unlikely Causality in the Association Between Soft Drink Consumption and Mortality. <i>JAMA Internal Medicine</i> , 2020, 180, 335. | 5.1 | 1 |
| 14 | Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling". <i>International Journal of Health Policy and Management</i> , 2020, 9, 352-355. | 0.9 | 1 |
| 15 | A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. <i>Journal of Asthma</i> , 2019, 56, 872-881. | 1.7 | 15 |
| 16 | Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: a Cost-Effectiveness Analysis. <i>Journal of General Internal Medicine</i> , 2019, 34, 846-854. | 2.6 | 20 |
| 17 | Early onset sepsis calculator-based management of newborns exposed to maternal intrapartum fever: a cost benefit analysis. <i>Journal of Perinatology</i> , 2019, 39, 571-580. | 2.0 | 15 |
| 18 | Now Is the Time for Transparency in Value-Based Healthcare Decision Modeling. <i>Value in Health</i> , 2019, 22, 564-569. | 0.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States. <i>Annals of Pharmacotherapy</i> , 2019, 53, 134-143. | 1.9 | 24 |
| 20 | Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function. <i>International Journal of Cardiology</i> , 2019, 282, 53-58. | 1.7 | 14 |
| 21 | Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-to-Severe Crohn's Disease in Biologic-Naïve Patients. <i>Pharmacotherapy</i> , 2019, 39, 118-128. | 2.6 | 9 |
| 22 | Lifestyle intervention for adults with spinal cord injury: Results of the USC's RLANRC Pressure Ulcer Prevention Study. <i>Journal of Spinal Cord Medicine</i> , 2019, 42, 2-19. | 1.4 | 25 |
| 23 | Cost-Effectiveness of a Technology-Facilitated Depression Care Management Adoption Model in Safety-Net Primary Care Patients with Type 2 Diabetes. <i>Value in Health</i> , 2018, 21, 561-568. | 0.3 | 25 |
| 24 | Consistent estimation of polychotomous treatment effects with selection-bias and unobserved heterogeneity using panel data correlated random coefficients model. <i>Health Services and Outcomes Research Methodology</i> , 2018, 18, 75-95. | 1.8 | 0 |
| 25 | Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 30. | 1.5 | 2 |
| 26 | Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. <i>Clinical Colorectal Cancer</i> , 2018, 17, e751-e761. | 2.3 | 37 |
| 27 | First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. <i>Lung Cancer</i> , 2018, 123, 166-171. | 2.0 | 31 |
| 28 | Comparative Effectiveness of a Technology-Facilitated Depression Care Management Model in Safety-Net Primary Care Patients With Type 2 Diabetes: 6-Month Outcomes of a Large Clinical Trial. <i>Journal of Medical Internet Research</i> , 2018, 20, e147. | 4.3 | 26 |
| 29 | A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIIa On-Demand. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 149-157. | 0.9 | 8 |
| 30 | A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2016, 63, 1495-1504. | 5.8 | 53 |
| 31 | Prescriber preferences for behavioural economics interventions to improve treatment of acute respiratory infections: a discrete choice experiment. <i>BMJ Open</i> , 2016, 6, e012739. | 1.9 | 13 |
| 32 | Effect of Behavioral Interventions on Inappropriate Antibiotic Prescribing Among Primary Care Practices. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 562. | 7.4 | 663 |
| 33 | Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015, 21, 641-647. | 0.9 | 4 |
| 34 | Understanding patient preferences and willingness to pay for hemophilia therapies. <i>Patient Preference and Adherence</i> , 2015, 9, 1623. | 1.8 | 24 |
| 35 | Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. <i>International Journal of Cardiology</i> , 2015, 181, 417-424. | 1.7 | 32 |
| 36 | Marijuana Use in Models for Health Outcomes. <i>American Journal of Medicine</i> , 2015, 128, e23. | 1.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Estimating the association between metabolic risk factors and marijuana use in U.S. adults using data from the continuous National Health and Nutrition Examination Survey. <i>Annals of Epidemiology</i> , 2015, 25, 486-491. | 1.9 | 22 |
| 38 | Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 267-283. | 1.4 | 13 |
| 39 | Promise of Precision Medicine. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1752. | 7.4 | 2 |
| 40 | A Special Commemorative Issue Honoring William S. Comanor and 50 Years of Pharmaceutical Economics. <i>International Journal of the Economics of Business</i> , 2015, 22, 165-168. | 1.7 | 0 |
| 41 | Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon- β 1a in Relapsing-Remitting Multiple Sclerosis. <i>CNS Drugs</i> , 2015, 29, 71-81. | 5.9 | 22 |
| 42 | Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 545-558. | 1.4 | 0 |
| 43 | Implementing trials of complex interventions in community settings: The USCâ€“Rancho Los Amigos Pressure Ulcer Prevention Study (PUPS). <i>Clinical Trials</i> , 2014, 11, 218-229. | 1.6 | 19 |
| 44 | Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 677-683. | 1.4 | 32 |
| 45 | A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments. <i>Pharmacoeconomics</i> , 2014, 32, 1201-1212. | 3.3 | 49 |
| 46 | Cost-Effectiveness Analysis of Abiraterone and Sipuleucel-T in Asymptomatic Metastatic Castration-Resistant Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1417-1425. | 4.9 | 27 |
| 47 | Current Issues in Pharmacoeconomic Modeling. <i>The Journal of Health Technology Assessment</i> , 2014, 2, 6-9. | 0.2 | 0 |
| 48 | INCREMENTAL EXPENDITURE OF BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC TREATMENT USING INSTRUMENTAL VARIABLES IN PANEL DATA. <i>Health Economics (United Kingdom)</i> , 2013, 22, 807-823. | 1.7 | 4 |
| 49 | Costâ€“benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). <i>Vaccine</i> , 2013, 31, 2558-2564. | 3.8 | 7 |
| 50 | Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. <i>BMC Pediatrics</i> , 2013, 13, 127. | 1.7 | 71 |
| 51 | Depression treatment preferences of older white and Mexican origin men. <i>General Hospital Psychiatry</i> , 2013, 35, 59-65. | 2.4 | 26 |
| 52 | Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States. <i>Pharmacoeconomics</i> , 2013, 31, 823-839. | 3.3 | 27 |
| 53 | Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. <i>Journal of Medical Economics</i> , 2013, 16, 1082-1088. | 2.1 | 6 |
| 54 | The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. <i>Neuro-Oncology</i> , 2013, 15, 1532-1542. | 1.2 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors. <i>Haemophilia</i> , 2013, 19, 711-719. | 2.1 | 3 |
| 56 | Cost-Effectiveness Analysis of the Bivalent and Quadrivalent Human Papillomavirus Vaccines from a Societal Perspective in Colombia. <i>PLoS ONE</i> , 2013, 8, e80639. | 2.5 | 17 |
| 57 | Costs of Necrotizing Enterocolitis and Cost-Effectiveness of Exclusively Human Milk-Based Products in Feeding Extremely Premature Infants. <i>Breastfeeding Medicine</i> , 2012, 7, 29-37. | 1.7 | 176 |
| 58 | Effectiveness of a lifestyle intervention in promoting the well-being of independently living older people: results of the Well Elderly 2 Randomised Controlled Trial. <i>Journal of Epidemiology and Community Health</i> , 2012, 66, 782-790. | 3.7 | 327 |
| 59 | Cost-Benefit Analysis of In-Hospital Influenza Vaccination of Postpartum Women. <i>Obstetrics and Gynecology</i> , 2012, 119, 306-314. | 2.4 | 13 |
| 60 | Cost-Effectiveness Analysis of Collaborative Care Management of Major Depression among Low-Income, Predominantly Hispanics with Diabetes. <i>Value in Health</i> , 2012, 15, 249-254. | 0.3 | 58 |
| 61 | Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity score and instrumental variable methods to adjust for treatment selection bias. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 470-484. | 1.9 | 19 |
| 62 | Efficacy of Bypassing Agents in Patients With Hemophilia and Inhibitors: A Systematic Review and Meta-Analysis. <i>Clinical Therapeutics</i> , 2012, 34, 434-445. | 2.5 | 11 |
| 63 | Antidepressant Use in Geriatric Populations: The Burden of Side Effects and Interactions and Their Impact on Adherence and Costs. <i>American Journal of Geriatric Psychiatry</i> , 2011, 19, 211-221. | 1.2 | 88 |
| 64 | Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors. <i>Haemophilia</i> , 2011, 17, e969-74. | 2.1 | 16 |
| 65 | Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa. <i>Journal of Medical Economics</i> , 2011, 14, 516-525. | 2.1 | 9 |
| 66 | Effectiveness of Collaborative Care in Addressing Depression Treatment Preferences Among Low-Income Latinos. <i>Psychiatric Services</i> , 2010, 61, 1112-1118. | 2.0 | 52 |
| 67 | Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report Part IV. <i>Value in Health</i> , 2010, 13, 18-24. | 0.3 | 22 |
| 68 | Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report Part II. <i>Value in Health</i> , 2010, 13, 8-13. | 0.3 | 120 |
| 69 | Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report Part III. <i>Value in Health</i> , 2010, 13, 14-17. | 0.3 | 21 |
| 70 | Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report Part VI. <i>Value in Health</i> , 2010, 13, 28-33. | 0.3 | 80 |
| 71 | Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report Part I. <i>Value in Health</i> , 2010, 13, 3-7. | 0.3 | 81 |
| 72 | Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report Part V. <i>Value in Health</i> , 2010, 13, 25-27. | 0.3 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Commentary on Knight <i>et al.</i> : A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. <i>Haemophilia</i> , 2010, 16, 366-368. | 2.1 | 5 |
| 74 | Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. <i>General Dentistry</i> , 2010, 58, 484-92; quiz 493-4. | 0.4 | 9 |
| 75 | Cost-effectiveness analysis of lapatinib in HER2-positive advanced breast cancer. <i>Cancer</i> , 2009, 115, 489-498. | 4.1 | 48 |
| 76 | Cost Impact of Diagnostic Imaging for Lower Extremity Peripheral Vascular Occlusive Disease. <i>Value in Health</i> , 2009, 12, 262-266. | 0.3 | 18 |
| 77 | Costs of second-generation antihistamines in the treatment of allergic rhinitis: US perspective. <i>Current Medical Research and Opinion</i> , 2009, 25, 1421-1431. | 1.9 | 7 |
| 78 | Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment. <i>Allergy and Asthma Proceedings</i> , 2009, 30, 634-642. | 2.2 | 13 |
| 79 | Asthma costs and utilization in a managed care organization. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 885-892.e5. | 2.9 | 35 |
| 80 | Using Pharmacoeconomics to Value Pharmacotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 197-200. | 4.7 | 11 |
| 81 | A six-year study of diagnostic lower extremity imaging practice patterns and outcomes in the Veterans Affairs health care system. <i>International Journal of Angiology</i> , 2008, 17, 78-82. | 0.6 | 1 |
| 82 | The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: A propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. <i>American Heart Journal</i> , 2007, 154, 267-277. | 2.7 | 63 |
| 83 | A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 2775-2787. | 1.8 | 21 |
| 84 | Prices, regulation and innovation in pharmaceuticals and biotechnology. <i>Research in Human Capital and Development</i> , 2007, , 81-99. | 0.1 | 1 |
| 85 | Cost Effectiveness of Tumour Necrosis Factor-?? Inhibitors as First-Line Agents in Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2006, 24, 1221-1232. | 3.3 | 47 |
| 86 | Comparing Patient Access to Pharmaceuticals in the??UK and US. <i>Applied Health Economics and Health Policy</i> , 2006, 5, 269-270. | 2.1 | 1 |
| 87 | Where's the Value in Health Care?. <i>Value in Health</i> , 2006, 9, 141-143. | 0.3 | 14 |
| 88 | Economic Considerations for Pertussis Booster Vaccination in Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, S127-S133. | 2.0 | 28 |
| 89 | Cost and Utilization Impacts of Oral Antihistamines in the California Medi-Cal Program. <i>Value in Health</i> , 2005, 8, 506-516. | 0.3 | 8 |
| 90 | The cost effectiveness of cardiovascular medicines. <i>Current Atherosclerosis Reports</i> , 2005, 7, 79-80. | 4.8 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | The Application of Cost-Effectiveness and Cost-Benefit Analysis to Pharmaceuticals. , 2005, , 225-248. | | 1 |
| 92 | Appropriate Econometric Methods for Pharmacoeconomic Studies of Retrospective Claims Data: An Introductory Guide. Journal of Managed Care Pharmacy, 2005, 11, 344-348. | 2.2 | 11 |
| 93 | Implementation and Outcomes of Commercial Disease Management Programs in the United States: The Disease Management Outcomes Consolidation Survey. Disease Management: DM, 2005, 8, 253-264. | 1.0 | 15 |
| 94 | Cost Effectiveness of Treating Low HDL-Cholesterol in the Primary Prevention of Coronary Heart Disease. Pharmacoeconomics, 2005, 23, 133-141. | 3.3 | 28 |
| 95 | Cost-Effectiveness Analysis of Rizatriptan and Sumatriptan versus Cafergot?? in the Acute Treatment of Migraine. CNS Drugs, 2005, 19, 635-642. | 5.9 | 13 |
| 96 | Medicare Coverage and Reimbursement of Outpatient Prescription Drugs in the US. Applied Health Economics and Health Policy, 2005, 4, 9-14. | 2.1 | 1 |
| 97 | Using Conjoint Analysis to Assess Depression Treatment Preferences Among Low-Income Latinos. Psychiatric Services, 2004, 55, 934-936. | 2.0 | 71 |
| 98 | Evaluation of Strategies for Use of Acellular Pertussis Vaccine in Adolescents and Adults: A Cost-Benefit Analysis. Clinical Infectious Diseases, 2004, 39, 20-28. | 5.8 | 107 |
| 99 | Cost-Effectiveness of Primary Implanted Cardioverter Defibrillator for Sudden Death Prevention in Congestive Heart Failure. Cardiovascular Drugs and Therapy, 2004, 18, 161-170. | 2.6 | 38 |
| 100 | Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD. Expert Review of Pharmacoeconomics and Outcomes Research, 2004, 4, 625-634. | 1.4 | 13 |
| 101 | Evaluation and review of pharmacoeconomic models. Expert Opinion on Pharmacotherapy, 2004, 5, 1867-1880. | 1.8 | 27 |
| 102 | Cost-Effectiveness Analysis of Pharmaceutical Care in a Medicare Drug Benefit Program. Value in Health, 2003, 6, 425-435. | 0.3 | 35 |
| 103 | Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies. Medical Care, 2003, 41, 32-44. | 2.4 | 253 |
| 104 | Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES. Journal of Managed Care Pharmacy, 2003, 9, 53-61. | 2.2 | 260 |
| 105 | Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. American Journal of Managed Care, 2003, 9, 45-56. | 1.1 | 24 |
| 106 | Hospital cost drivers: an evaluation of 1998-2001 state-level data. American Journal of Managed Care, 2003, 9 Spec No 1, SP13-24. | 1.1 | 11 |
| 107 | Cost-Effectiveness of Preventive Occupational Therapy for Independent-Living Older Adults. Journal of the American Geriatrics Society, 2002, 50, 1381-1388. | 2.6 | 106 |
| 108 | Pharmacoeconomic Guidelines: Where Do We Go from Here?. Value in Health, 2001, 4, 211. | 0.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Commentary: Pharmacoeconomics and Outcomes Research: Expanding the Healthcare "Outcomes" Market. Value in Health, 2000, 3, 181-185. | 0.3 | 1 |
| 110 | An economic cost analysis of oral ganciclovir prophylaxis for the prevention of CMV disease. , 2000, 17, 911-919. | | 3 |
| 111 | Pharmacoeconomics: Identifying the Issues Overview and Advisory Panel Report Summary. Value in Health, 1999, 2, 67-72. | 0.3 | 3 |
| 112 | Panel 2: Methodological Issues in Conducting Pharmacoeconomic Evaluations" Modeling Studies. Value in Health, 1999, 2, 78-81. | 0.3 | 28 |
| 113 | Health Care Costs and Outcomes: How Should We Evaluate Real World Data?. Value in Health, 1999, 2, 417-419. | 0.3 | 11 |
| 114 | Pharmacoeconomics of Lipid-Lowering Agents for Primary and Secondary Prevention of Coronary Artery Disease. Pharmacoeconomics, 1999, 15, 47-74. | 3.3 | 77 |
| 115 | Introduction to the ISPOR Lipid Conference. Value in Health, 1998, 1, 95-99. | 0.3 | 1 |
| 116 | A Direction for Value in Health. Value in Health, 1998, 1, 149-154. | 0.3 | 1 |
| 117 | The ISPOR Lipid Conference: Pharmacoeconomics and Outcomes Modeling Issues. Value in Health, 1998, 1, 155-158. | 0.3 | 0 |
| 118 | Economic Modeling and Sensitivity Analysis. Value in Health, 1998, 1, 187-193. | 0.3 | 14 |
| 119 | From Research into Practice: How Should Healthcare Organizations/Governments Decide about Lipid Therapy and Who Will Pay? Reactor Panel and Open Forum. Value in Health, 1998, 1, 243-250. | 0.3 | 0 |
| 120 | The Kaiser Permanente/USC Patient Consultation Study: Change in use and cost of health care services. American Journal of Health-System Pharmacy, 1998, 55, 2485-2499. | 1.0 | 31 |
| 121 | Cost of lipid-lowering statin drugs. American Journal of Cardiology, 1996, 77, 225-226. | 1.6 | 3 |
| 122 | Cost-Effectiveness of Pravastatin in Secondary Prevention of Coronary Artery Disease**This study was supported by Bristol-Myers Squibb, Plainsboro, New Jersey.. American Journal of Cardiology, 1996, 78, 409-414. | 1.6 | 99 |
| 123 | Measuring the impact of patient counseling in the outpatient pharmacy setting: the research design of the Kaiser permanente/USC patient consultation study. Clinical Therapeutics, 1995, 17, 1188-1206. | 2.5 | 19 |
| 124 | Comment: Evaluation of Pharmacoeconomic Studies: Utilization of a Checklist. Annals of Pharmacotherapy, 1994, 28, 539-539. | 1.9 | 1 |
| 125 | Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 1992, 14, 309-317. | 2.2 | 222 |
| 126 | Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 1992, 14, 318-327. | 2.2 | 107 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. <i>American Journal of Cardiology</i> , 1991, 67, 789-796. | 1.6 | 69 |
| 128 | Cost-benefit analysis of Haemophilus influenzae type b prevention. <i>Pediatric Infectious Disease Journal</i> , 1990, 9, 246-251. | 2.0 | 38 |
| 129 | Medical costs of coronary artery disease in the United States. <i>American Journal of Cardiology</i> , 1990, 65, 432-440. | 1.6 | 93 |
| 130 | Econometric issues in modeling the costs of AIDS. <i>Health Policy</i> , 1989, 11, 125-145. | 3.0 | 14 |
| 131 | Ordinary Least Squares and Sample-Selection Models of Health-Care Demand: Monte Carlo Comparison. <i>Journal of Business and Economic Statistics</i> , 1987, 5, 499. | 2.9 | 20 |
| 132 | Medicare Pricing Mechanisms for Physician Services: An Overview of Alternative Approaches. <i>Medical Care Review</i> , 1986, 43, 59-100. | 0.9 | 1 |
| 133 | Let Them Eat Cake: A Note on Comparing Alternative Models of the Demand for Medical Care. <i>Journal of Business and Economic Statistics</i> , 1984, 2, 279. | 2.9 | 46 |
| 134 | The Impact of Public Health Care Financing Policies on Private-Sector Hospital Costs. <i>Journal of Health Politics, Policy and Law</i> , 1983, 7, 945-952. | 1.9 | 24 |
| 135 | Physician-induced demand. <i>Journal of Health Economics</i> , 1982, 1, 231-244. | 2.7 | 57 |
| 136 | Effects of fluoride and regular dental care on personal dental expenditures of young adults in Finland. <i>Community Dentistry and Oral Epidemiology</i> , 1982, 10, 15-22. | 1.9 | 3 |